Literature DB >> 20807770

Oligomeric amyloid-{beta} inhibits the proteolytic conversion of brain-derived neurotrophic factor (BDNF), AMPA receptor trafficking, and classical conditioning.

Zhaoqing Zheng1, Boris Sabirzhanov, Joyce Keifer.   

Abstract

Amyloid-β (Aβ) peptide is thought to have a significant role in the progressive memory loss observed in patients with Alzheimer disease and inhibits synaptic plasticity in animal models of learning. We previously demonstrated that brain-derived neurotrophic factor (BDNF) is critical for synaptic AMPA receptor delivery in an in vitro model of eyeblink classical conditioning. Here, we report that acquisition of conditioned responses was significantly attenuated by bath application of oligomeric (200 nm), but not fibrillar, Aβ peptide. Western blotting revealed that BDNF protein expression during conditioning is significantly reduced by treatment with oligomeric Aβ, as were phosphorylation levels of cAMP-response element-binding protein (CREB), Ca(2+)/calmodulin-dependent protein kinase II (CaMKII), Ca(2+)/calmodulin-dependent protein kinase IV (CaMKIV), and ERK. However, levels of PKA and PKCζ/λ were unaffected, as was PDK-1. Protein localization studies using confocal imaging indicate that oligomeric Aβ, but not fibrillar or scrambled forms, suppresses colocalization of GluR1 and GluR4 AMPA receptor subunits with synaptophysin, indicating that trafficking of these subunits to synapses during the conditioning procedure is blocked. In contrast, coapplication of BDNF with oligomeric Aβ significantly reversed these findings. Interestingly, a tolloid-like metalloproteinase in turtle, tTLLs (turtle tolloid-like protein), which normally processes the precursor proBDNF into mature BDNF, was found to degrade oligomeric Aβ into small fragments. These data suggest that an Aβ-induced reduction in BDNF, perhaps due to interference in the proteolytic conversion of proBDNF to BDNF, results in inhibition of synaptic AMPA receptor delivery and suppression of the acquisition of conditioning.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807770      PMCID: PMC2966086          DOI: 10.1074/jbc.M110.150821

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Protein kinase C-dependent and independent signaling pathways regulate synaptic GluR1 and GluR4 AMPAR subunits during in vitro classical conditioning.

Authors:  Z Zheng; J Keifer
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

2.  Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ.

Authors:  Ping Yan; Xiaoyan Hu; Haowei Song; Kejie Yin; Randall J Bateman; John R Cirrito; Qingli Xiao; Fong F Hsu; John W Turk; Jan Xu; Chung Y Hsu; David M Holtzman; Jin-Moo Lee
Journal:  J Biol Chem       Date:  2006-06-20       Impact factor: 5.157

3.  Properties of conditioned abducens nerve responses in a highly reduced in vitro brain stem preparation from the turtle.

Authors:  C W Anderson; J Keifer
Journal:  J Neurophysiol       Date:  1999-03       Impact factor: 2.714

4.  Brain-derived neurotrophic factor-dependent unmasking of "silent" synapses in the developing mouse barrel cortex.

Authors:  Chiaki Itami; Fumitaka Kimura; Tomoko Kohno; Masato Matsuoka; Masumi Ichikawa; Tadaharu Tsumoto; Shun Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

5.  Cleavage of proBDNF to BDNF by a tolloid-like metalloproteinase is required for acquisition of in vitro eyeblink classical conditioning.

Authors:  Joyce Keifer; Boris E Sabirzhanov; Zhaoqing Zheng; Wei Li; Timothy G Clark
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

6.  Conversion of silent synapses into the active pool by selective GluR1-3 and GluR4 AMPAR trafficking during in vitro classical conditioning.

Authors:  Maxim Mokin; Zhaoqing Zheng; Joyce Keifer
Journal:  J Neurophysiol       Date:  2007-06-27       Impact factor: 2.714

7.  {beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution.

Authors:  Zhenglin Gu; Wenhua Liu; Zhen Yan
Journal:  J Biol Chem       Date:  2009-02-24       Impact factor: 5.157

8.  In vitro classical conditioning of abducens nerve discharge in turtles.

Authors:  J Keifer; K E Armstrong; J C Houk
Journal:  J Neurosci       Date:  1995-07       Impact factor: 6.167

9.  Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease.

Authors:  Alan H Nagahara; David A Merrill; Giovanni Coppola; Shingo Tsukada; Brock E Schroeder; Gideon M Shaked; Ling Wang; Armin Blesch; Albert Kim; James M Conner; Edward Rockenstein; Moses V Chao; Edward H Koo; Daniel Geschwind; Eliezer Masliah; Andrea A Chiba; Mark H Tuszynski
Journal:  Nat Med       Date:  2009-02-08       Impact factor: 53.440

10.  Alzheimer's disease: synaptic dysfunction and Abeta.

Authors:  Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Neurodegener       Date:  2009-11-23       Impact factor: 14.195

View more
  16 in total

1.  Dysregulated phosphorylation of Ca(2+) /calmodulin-dependent protein kinase II-α in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease.

Authors:  Lindsay C Reese; Fernanda Laezza; Randall Woltjer; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-09-28       Impact factor: 5.372

2.  The effect of NAD-299 and TCB-2 on learning and memory, hippocampal BDNF levels and amyloid plaques in Streptozotocin-induced memory deficits in male rats.

Authors:  Simin Afshar; Siamak Shahidi; Ali Haeri Rohani; Alireza Komaki; Sara Soleimani Asl
Journal:  Psychopharmacology (Berl)       Date:  2018-07-19       Impact factor: 4.530

3.  Delta-secretase-cleaved Tau antagonizes TrkB neurotrophic signalings, mediating Alzheimer's disease pathologies.

Authors:  Jie Xiang; Zhi-Hao Wang; Eun Hee Ahn; Xia Liu; Shan-Ping Yu; Fredric P Manfredsson; Ivette M Sandoval; Gong Ju; Shengxi Wu; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-19       Impact factor: 11.205

Review 4.  The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.

Authors:  Niklas Reich; Christian Hölscher
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

5.  The protection of acetylcholinesterase inhibitor on β-amyloid-induced the injury of neurite outgrowth via regulating axon guidance related genes expression in neuronal cells.

Authors:  Jiao-Ning Shen; Deng-Shun Wang; Rui Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-10-20

Review 6.  Routes, destinations and delays: recent advances in AMPA receptor trafficking.

Authors:  Jeremy M Henley; Ellen A Barker; Oleg O Glebov
Journal:  Trends Neurosci       Date:  2011-03-21       Impact factor: 13.837

7.  Cell surface expression of the major amyloid-β peptide (Aβ)-degrading enzyme, neprilysin, depends on phosphorylation by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and dephosphorylation by protein phosphatase 1a.

Authors:  Naomasa Kakiya; Takashi Saito; Per Nilsson; Yukio Matsuba; Satoshi Tsubuki; Nobuyuki Takei; Hiroyuki Nawa; Takaomi C Saido
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

8.  Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter Aβ or tau pathology.

Authors:  Nicholas A Castello; Kim N Green; Frank M LaFerla
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

Review 9.  AMPA receptor trafficking and the mechanisms underlying synaptic plasticity and cognitive aging.

Authors:  Jeremy M Henley; Kevin A Wilkinson
Journal:  Dialogues Clin Neurosci       Date:  2013-03       Impact factor: 5.986

10.  Characterization of Aldh2 (-/-) mice as an age-related model of cognitive impairment and Alzheimer's disease.

Authors:  Yohan D'Souza; Ahmed Elharram; Raquel Soon-Shiong; R David Andrew; Brian M Bennett
Journal:  Mol Brain       Date:  2015-04-25       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.